FSH in the treatment of oligozoospermia.
The aim of this study was to individuate parameters able to distinguish oligozoospermic subjects who will respond to follicle-stimulating hormone (FSH) therapy. A group of 135 oligozoospermic subjects was divided in three groups considering basal FSH and inhibin B concentrations: group A (normal FSH and inhibin B) characterized by moderate hypospermatogenesis sometimes associated to partial spermatidic arrest; group B (high FSH and normal inhibin B) characterized by hypospermatogenesis associated or not to spermatogonial/spermatocytic arrest; group C (high FSH and low inhibin B) characterized by severe hypospermatogenesis. Seventy-eight patients were treated with FSH at the dose of 75 IU on alternate days while 57 were treated with the same dose every day for 3 months. After FSH treatment a significant increase in ejaculated sperm concentration was observed only in oligozoospermic subjects with normal basal FSH and inhibin B plasma levels (group A) showing a testicular cytological picture of moderate hypospermatogenesis. In these subjects no differences in sperm production were observed between the two protocols of therapy. In the remaining patients of group A, characterized by hypospermatogenesis associated with maturation arrest at spermatidic level and in group B and C, no increase in sperm concentration was observed after therapy. These data suggest that FSH treatment may have a role in oligozoospermic subjects only when the spermatogenetic alterations consist in germ cell depopulation without maturative disturbances and with normal FSH concentrations.
Foresta
C
C
Department of Medical and Surgical Sciences, University of Padova, Clinica Medica 3, Via Ospedale 105, 35128, Padova, Italy. forestac@protec.it
Bettella
A
A
Merico
M
M
Garolla
A
A
Plebani
M
M
Ferlin
A
A
Rossato
M
M
D000328:Adult; D001707:Biopsy, Needle; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D006801:Humans; D007265:Inhibins / Q000097:blood / Q000187:drug effects / Q000494:pharmacology; D008297:Male; D009845:Oligospermia / Q000188:drug therapy* / Q000473:pathology; D013091:Spermatogenesis / Q000187:drug effects; D013094:Spermatozoa / Q000166:cytology / Q000187:drug effects
D007265:Inhibins; D005640:Follicle Stimulating Hormone